April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Risk Factors for the Development or Progression of Tractional Retinal Detachment (TRD) After Intravitreal Bevacizumab (Avastin) Used as an Adjuvant to Vitrectomy for the Management of Severe Proliferative Diabetic Retinopathy (PDR)
L. Saldarriaga; J. Arevalo; J. G. Sanchez; M. H. Berrocal; J. J. Fromow-Guerra; L. Wu; M. Maia; M. J. Saravia; J. Bareño; for the Pan-American Collaborative Retina Study Group
Author Affiliations & Notes
  • L. Saldarriaga
    Retina & Vitreous Svc,
    Instituto Nacional de Investigación en Oftalmologia (INIO), Medellin, Colombia
  • J. Arevalo
    Retina and Vitreous, Clinica Oftal Centro Caracas, Caracas, Venezuela
  • J. G. Sanchez
    Retina & Vitreous Svc,
    Instituto Nacional de Investigación en Oftalmologia (INIO), Medellin, Colombia
  • M. H. Berrocal
    University of Puerto Rico, San Juan, Puerto Rico
  • J. J. Fromow-Guerra
    Retina, Association Para Evitar la Ceguera, Mexico City, Mexico
  • L. Wu
    Vitreoretinal, Instituto De Cirugia Ocular, San Jose, Costa Rica
  • M. Maia
    Retina & Vitreous Svc, The Universidade Federal de São Paulo, Departamento de Oftalmologia, Instituto da Visão, São Paulo, Brazil
  • M. J. Saravia
    Ophthalmology /Retina, Hospital Austral, Buenos Aires, Argentina
  • J. Bareño
    Epidemiology,
    Instituto Nacional de Investigación en Oftalmologia (INIO), Medellin, Colombia
  • for the Pan-American Collaborative Retina Study Group
    Instituto Nacional de Investigación en Oftalmologia (INIO), Medellin, Colombia
  • Footnotes
    Commercial Relationships  L. Saldarriaga, None; J. Arevalo, None; J.G. Sanchez, None; M.H. Berrocal, None; J.J. Fromow-Guerra, None; L. Wu, None; M. Maia, None; M.J. Saravia, None; J. Bareño, None.
  • Footnotes
    Support  in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4239. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Risk Factors for the Development or Progression of Tractional Retinal Detachment (TRD) After Intravitreal Bevacizumab (Avastin) Used as an Adjuvant to Vitrectomy for the Management of Severe Proliferative Diabetic Retinopathy (PDR)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      L. Saldarriaga, J. Arevalo, J. G. Sanchez, M. H. Berrocal, J. J. Fromow-Guerra, L. Wu, M. Maia, M. J. Saravia, J. Bareño, for the Pan-American Collaborative Retina Study Group; Risk Factors for the Development or Progression of Tractional Retinal Detachment (TRD) After Intravitreal Bevacizumab (Avastin) Used as an Adjuvant to Vitrectomy for the Management of Severe Proliferative Diabetic Retinopathy (PDR). Invest. Ophthalmol. Vis. Sci. 2010;51(13):4239.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : To determine the risk factors for the development or progression of TRD after intravitreal bevacizumab (Avastin) used as an adjuvant to vitrectomy for the management of severe PDR.

Methods: : Multicenter retrospective interventional study at 6 centers from 6 countries. The clinical charts of patients who experienced the development or progression of TRD after an intravitreal injection of 1.25 or 2.5 mg of bevacizumab before vitrectomy for the management of PDR were reviewed. Twenty-five eyes (patients) out of 698 intravitreal injections that developed or had progression of TRD were identified. Nineteen (73%) eyes had received a dose of 1.25 mg, and 6 (27%) eyes had received a dose of 2.5 mg. Clinical parameters of these patients previously identified as potential risk factors for TRD were obtained and analyzed and compared to the clinical characteristics of those patients that did not developed a TRD after IVB for PDR. Statistical analysis was performed using a bivariate analysis (Stata version 10.1).

Results: : Twenty-five eyes (patients) out of 698 intravitreal injections (3.6%) developed or had progression of TRD after intravitreal bevacizumab (1.25 mg: 19 TRD out of 626 injections: 3%; 2.5 mg: 6 TRD out of 72 injections: 8.3%). Risk factors for TRD after IVB identified in our study included, more than 15 years from the diagnosis of diabetes mellitus (DM) (p = 0.009), (OR = 0.30), (95CI = 0.10 - 0.83), (RR= 0.35), more than 13 days from injection to vitrectomy (p = 0.0001), (OR = 9.9), (95CI = 3.4 - 29), (RR = 6.9) and the use of a higher dose (2.5 mg) of bevacizumab (p = 0.022), (OR = 2.7), (95CI= 1.05 - 7.18), (RR = 2.38).

Conclusions: : The use of IVB as an adjuvant to vitrectomy for the management of severe PDR may be associated to the development or progression of TDR. Based on this bivariate analysis, risk factors for TRD after IVB in PDR are time from diagnosis of DM of more than 15 years, time interval from IVB to vitrectomy of more than 13 days, and the use of the higher dose of IVB (2.5 mg).

Keywords: diabetic retinopathy • retinal detachment • vascular endothelial growth factor 
© 2010, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept